Is Duavee Safe While Breastfeeding? What Every Woman Needs to Know

What Is Duavee and Who Is It Actually For?

Duavee is a combination of conjugated estrogens 0.45 mg and bazedoxifene 20 mg approved by the FDA in 2013 for two indications in postmenopausal women who still have a uterus: moderate-to-severe vasomotor symptoms (hot flashes and night sweats) and prevention of postmenopausal osteoporosis. It is the only currently approved tissue-selective estrogen complex (TSEC) in the United States.

The critical framing point: Duavee is a postmenopausal drug. Its approved population is women who are no longer having menstrual periods and who are not pregnant or breastfeeding. Bazedoxifene, a selective estrogen receptor modulator (SERM), replaces the progestogen component typically used with estrogen to protect the uterine lining. Because bazedoxifene carries its own reproductive-toxicity profile, this combination is expressly excluded from use during pregnancy and lactation.

How Each Component Works

Conjugated estrogens are a mixture of estrogens derived from equine sources. They bind estrogen receptors in the hypothalamus, bone, vaginal epithelium, and breast. In postmenopausal women, exogenous estrogen relieves vasomotor symptoms and slows bone resorption.

Bazedoxifene acts as an estrogen agonist in bone and an antagonist in breast and uterine tissue. This dual action means it can suppress endometrial proliferation caused by the estrogen component without requiring a separate progestogen. In breast tissue, bazedoxifene behaves as an antagonist, which is part of why the SMART trials evaluated this combination as potentially favorable for breast safety.

Why This Matters for Life Stage

A woman who is breastfeeding is, by definition, in the postpartum period. Her hormonal milieu is dominated by elevated prolactin, suppressed gonadotropins, and low circulating estrogen. Introducing exogenous estrogen into this environment is clinically problematic for two reasons: it may suppress milk production, and neither component of Duavee has been studied in lactating women or infants.

Pregnancy and Duavee: A Clear Contraindication

Duavee is contraindicated in pregnancy. This is not a relative caution. The FDA prescribing information states explicitly that Duavee should not be used by women who are or may be pregnant. Under older FDA pregnancy category labeling this combination carried a Category X designation for bazedoxifene, meaning risks clearly outweigh any possible benefit.

Conjugated Estrogens in Pregnancy

Exogenous estrogens administered during pregnancy have been associated with fetal harm in animal studies and, historically, with adverse outcomes in humans when diethylstilbestrol (a synthetic estrogen) was used. While conjugated estrogens are not DES, ACOG advises against initiating any systemic estrogen therapy during pregnancy absent a specific, well-documented clinical indication reviewed by a specialist.

There are no adequate, well-controlled human trials of Duavee in pregnant women. Animal studies with bazedoxifene showed embryo-fetal toxicity and skeletal malformations at exposures below the human therapeutic dose, as noted in the FDA label reproductive toxicology section.

Bazedoxifene: Reproductive Toxicity in Animal Data

Bazedoxifene has demonstrated teratogenic potential in preclinical models. In rabbit developmental toxicity studies, bazedoxifene produced skeletal malformations at doses approximating or below the human clinical dose of 20 mg/day. Rat studies showed delayed ossification and reduced fetal weight. There is no human pregnancy registry for this compound, and no case series large enough to draw safety conclusions.

What to Do If You Become Pregnant While Taking Duavee

Stop the medication immediately. Contact your prescribing clinician and your obstetric provider. Because Duavee is labeled for postmenopausal women, an unexpected pregnancy in that population is rare but not impossible in perimenopause. Any woman in the late perimenopause transition who still has any chance of ovulation should be counseled explicitly about contraception before starting estrogen-containing therapies.

Breastfeeding and Duavee: Why It Is Not Safe

The answer is direct. You should not take Duavee while breastfeeding. Two separate mechanisms explain why.

Estrogen Suppresses Milk Production

Prolactin drives milk synthesis after delivery. High circulating estrogen suppresses prolactin secretion at the hypothalamic-pituitary axis. This is the physiological reason estrogen levels drop sharply at delivery: the placenta, which had been the dominant source of estrogen, is delivered, and prolactin rises in response. Research on lactation physiology consistently shows that exogenous estrogen given in the early postpartum period reduces milk volume, and even low-dose estrogen-containing contraceptives can diminish supply if initiated before lactation is well established.

Conjugated estrogens are absorbed systemically and will reduce prolactin-driven milk synthesis. The 0.45 mg dose in Duavee, while lower than older higher-dose estrogen formulations, is not exempt from this effect. The National Institutes of Health LactMed database flags estrogen-containing products as potentially milk-supply-reducing and advises against use during established breastfeeding unless there is a compelling clinical reason with close monitoring.

Bazedoxifene: No Human Lactation Data

Bazedoxifene has no published human pharmacokinetic data during lactation. There are no studies measuring bazedoxifene concentrations in breast milk, no infant plasma level data, and no follow-up studies of nursing infants whose mothers received this drug. LactMed lists the absence of data as itself a safety signal: when a compound with known tissue-selective estrogen receptor modulator activity and preclinical reproductive toxicity has zero published human lactation studies, the default recommendation is avoidance.

SERMs as a class have biological plausibility for infant harm. Tamoxifen, another SERM, is specifically listed by LactMed as contraindicated during breastfeeding due to its estrogen-receptor activity and potential developmental effects in neonates. Bazedoxifene belongs to the same pharmacological class. Extrapolating tamoxifen's contraindication to bazedoxifene is not definitive, but it is the most clinically cautious and scientifically grounded position available given the data gap.

The Data Gap Is Real

To be transparent with you: the safety concern about bazedoxifene in lactation is based on extrapolation from animal data, SERM class effects, and the absence of human evidence, not on documented infant harm. Women have been under-represented in drug trials for decades, and lactating women are almost never included in phase 3 trials of non-obstetric drugs. That absence of evidence is not evidence of safety. The pharmacological mechanisms for harm are credible. The lack of human lactation studies for a drug approved in 2013 reflects a systematic gap in reproductive pharmacology research, not reassuring safety data.

Clinicians and regulatory agencies have made the conservative call: no use during breastfeeding. That call is appropriate.

Sex-Specific Pharmacology: How Estrogen and SERMs Behave Differently in Women Across Life Stages

Estrogen receptor distribution and sensitivity change dramatically across a woman's reproductive life. In reproductive-age women, endogenous estradiol levels typically range from 25 to 400 pg/mL across the menstrual cycle, dwarfing the pharmacological contribution of a 0.45 mg conjugated estrogen dose. In postmenopausal women, where endogenous estradiol may be below 10 pg/mL, the same dose produces a meaningful pharmacological effect.

This life-stage difference is why Duavee is effective in its target population and why giving it to a breastfeeding woman creates a pharmacologically mismatched situation. A postpartum lactating woman already has elevated prolactin and a complex hormonal recovery underway. Introducing a SERM with estrogen adds competing receptor signals in breast tissue, the uterus, and the hypothalamic-pituitary axis at a time when that system is actively regulated around lactation.

Perimenopause vs. Postmenopause: Clarifying the Target Population

Duavee is not approved for perimenopausal symptom management. Perimenopause, the years leading up to the final menstrual period, is characterized by erratic estrogen levels, irregular cycles, and continued ovulation potential. A woman in perimenopause who is not breastfeeding and has menopausal-type symptoms is not the approved indication. The Menopause Society (formerly NAMS) recommends that systemic hormone therapy, including combination preparations like Duavee, be used in women who have reached menopause, defined as 12 consecutive months without a menstrual period.

Osteoporosis Prevention: The Context for Prescribing

Duavee's second indication is osteoporosis prevention, not treatment of established fractures. The SMART-1 trial showed that conjugated estrogens 0.45 mg/bazedoxifene 20 mg increased lumbar spine bone mineral density significantly compared with placebo over 12 months in postmenopausal women. Women in the breastfeeding period, while they do experience transient bone mineral density loss due to calcium mobilization for milk production, are not candidates for Duavee. That bone loss typically reverses after weaning, and the risk-benefit calculation does not support estrogen-SERM therapy in this group.

Who This Drug Is Right For and Who It Is Not

Women Who May Be Appropriate Candidates

Duavee is designed for a specific, narrow group:

• Postmenopausal women with an intact uterus who have moderate-to-severe hot flashes that meaningfully impair daily function or sleep
• Women for whom osteoporosis prevention is a concurrent goal and who prefer to avoid a separate bisphosphonate or progestogen
• Women who have tried or are unable to tolerate standard estrogen-plus-progestogen hormone therapy

Women for Whom Duavee Is Not Appropriate

• Pregnant women. Full stop.
• Breastfeeding women. Full stop.
• Women who have had a hysterectomy (standard estrogen alone is simpler and has more long-term data)
• Women with a history of estrogen-sensitive breast cancer or active breast cancer
• Women with a personal history of venous thromboembolism, stroke, or active liver disease, given the class-level cardiovascular and thromboembolic risks of estrogen therapy noted in the FDA label
• Perimenopausal women who may still be ovulating and are not using effective contraception
• Women with unexplained vaginal bleeding

What Are the Alternatives If You Are Breastfeeding and Have Menopausal-Type Symptoms?

This question comes up less often than it might seem, because most breastfeeding women are not postmenopausal. Postpartum estrogen deficiency, however, is real and can cause hot flashes, night sweats, vaginal dryness, and mood changes in the weeks to months after delivery. If you are experiencing these symptoms while nursing, the cause is postpartum hormonal recovery, not menopause, and the management approach differs.

Non-Hormonal Options Compatible with Breastfeeding

• Low-dose SSRIs/SNRIs: Paroxetine 7.5 mg (Brisdelle) is the only FDA-approved non-hormonal vasomotor symptom treatment. Paroxetine and sertraline have the most breastfeeding safety data among antidepressants in nursing mothers, with low infant plasma levels in published studies. Discuss this with your provider before starting.
• Fezolinetant (Veozah): A neurokinin 3 receptor antagonist approved in 2023 for vasomotor symptoms. No lactation data exist; advise avoidance until data emerge.
• Lifestyle measures: Cooling fans, layered clothing, reduced alcohol and caffeine, and temperature-controlled sleeping environments reduce vasomotor symptom burden in some women, though the effect size is modest.
• Vaginal estrogen for local symptoms: Low-dose vaginal estradiol (cream, ring, or tablet) has minimal systemic absorption. Published data show very low systemic absorption from vaginal estradiol 10 mcg tablets. Most clinicians consider low-dose vaginal estrogen compatible with breastfeeding for genitourinary symptoms, though this decision should be made with your clinician on an individual basis.

After Weaning

Once breastfeeding stops and your prolactin levels normalize, if you are postmenopausal by clinical definition, you can revisit estrogen therapy options with your clinician. If you are in your reproductive years and experiencing premature ovarian insufficiency, a separate clinical evaluation is warranted before initiating any hormone therapy.

Contraception Considerations for Women Prescribed Estrogen-Containing Therapies

Any woman in the perimenopausal transition who is starting estrogen therapy should have an explicit contraception conversation with her clinician. Estrogen-containing preparations are not contraceptives. Bazedoxifene, as a SERM, is not a contraceptive. Pregnancy in a woman taking Duavee would be both unexpected and concerning given the drug's teratogenic risk.

ACOG recommends that women in perimenopause continue effective contraception until they have been amenorrheic for 12 consecutive months if they are under 50, and for a shorter interval guided by individual assessment if over 50. A woman cannot be certain she is postmenopausal until that 12-month mark, which is why contraception counseling before initiating any hormone therapy is a required part of prescribing.

Key Safety Signals to Know Before Your Appointment

If you are considering Duavee for your own postmenopausal symptoms, bring these points to your clinician:

1. Thromboembolic risk: Oral estrogen increases VTE risk. The absolute risk is low in healthy postmenopausal women aged 50 to 59, but it is real. Ask about your personal risk factors.
2. Breast cancer screening: All women on estrogen therapy should have up-to-date mammography. The Women's Health Initiative (WHI, 2002) raised concerns about combined estrogen-progestogen therapy and breast cancer risk. Duavee uses a SERM instead of a progestogen, and 12-month breast safety data from the SMART trials were reassuring, but long-term data beyond two years remain limited.
3. Endometrial protection: The bazedoxifene component is specifically intended to protect the uterine lining. Missing doses or switching formulations without medical guidance could reduce this protection.
4. Liver disease: Both conjugated estrogens and bazedoxifene are hepatically metabolized. Active liver disease is a contraindication.

A WomanRx editorial board member (OB-GYN, NAMS-certified) offered this clinical framing for readers: "The question I hear most often is whether low-dose estrogen is 'safe enough' to use while breastfeeding. The honest answer is that we don't know for bazedoxifene specifically, and that uncertainty alone is enough to recommend against it. For the estrogen component, we have good mechanistic reasons to expect milk suppression. Telling a patient 'the data are absent' is not the same as telling her it's safe."